{"id":"cc-220","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Neutropenia"},{"rate":"5-15%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL3916385","moleculeType":"Small molecule","molecularWeight":"502.67"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By binding to cereblon, CC-220 enhances the degradation of Ikaros and Aiolos, transcription factors that play a role in B-cell and T-cell function, thereby reducing their activity and dampening immune responses associated with autoimmune diseases.","oneSentence":"CC-220 is a small molecule that modulates the activity of cereblon, an E3 ubiquitin ligase, leading to the degradation of specific proteins involved in inflammation and immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:49:46.894Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07437963","phase":"PHASE1, PHASE2","title":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-01","conditions":"Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma","enrollment":76},{"nctId":"NCT06179888","phase":"PHASE2","title":"Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-27","conditions":"Multiple Myeloma","enrollment":78},{"nctId":"NCT06465316","phase":"PHASE1","title":"Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-06","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":26},{"nctId":"NCT06215118","phase":"PHASE1","title":"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-20","conditions":"Multiple Myeloma","enrollment":87},{"nctId":"NCT06232044","phase":"PHASE1, PHASE2","title":"Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-04-23","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":88},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT05169515","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-26","conditions":"Non-Hodgkin Lymphoma","enrollment":121},{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":"Multiple Myeloma","enrollment":75},{"nctId":"NCT06348108","phase":"PHASE1","title":"Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alfred Chung, MD","startDate":"2025-07-28","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":32},{"nctId":"NCT05827016","phase":"PHASE3","title":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-22","conditions":"Multiple Myeloma","enrollment":1216},{"nctId":"NCT05434689","phase":"PHASE1, PHASE2","title":"COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-18","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT05199311","phase":"PHASE1, PHASE2","title":"Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2022-05-13","conditions":"Multiple Myeloma","enrollment":66},{"nctId":"NCT06121843","phase":"PHASE1","title":"A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-02-22","conditions":"Multiple Myeloma","enrollment":147},{"nctId":"NCT04884035","phase":"PHASE1","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","status":"RECRUITING","sponsor":"Celgene","startDate":"2021-09-15","conditions":"Lymphoma, B-Cell","enrollment":174},{"nctId":"NCT05560399","phase":"EARLY_PHASE1","title":"A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-02-06","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT06518551","phase":"PHASE1, PHASE2","title":"Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM","status":"RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2024-11-01","conditions":"Myeloma, Multiple Myeloma, Refractory Multiple Myeloma","enrollment":49},{"nctId":"NCT05392946","phase":"PHASE1, PHASE2","title":"Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-08-11","conditions":"Plasma Cell Myeloma","enrollment":49},{"nctId":"NCT06785415","phase":"PHASE1, PHASE2","title":"Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-03-18","conditions":"Recurrent Multiple Myeloma","enrollment":37},{"nctId":"NCT04776395","phase":"PHASE2","title":"Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-11-02","conditions":"Smoldering Plasma Cell Myeloma","enrollment":68},{"nctId":"NCT04855136","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma","status":"TERMINATED","sponsor":"Celgene","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":21},{"nctId":"NCT04975997","phase":"PHASE3","title":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2022-06-23","conditions":"Multiple Myeloma","enrollment":864},{"nctId":"NCT04464798","phase":"PHASE1","title":"A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas","status":"TERMINATED","sponsor":"Celgene","startDate":"2020-11-11","conditions":"Lymphoma","enrollment":62},{"nctId":"NCT04392037","phase":"PHASE2","title":"Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2021-02-17","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04564703","phase":"PHASE2","title":"Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2021-02-22","conditions":"Multiple Myeloma","enrollment":160},{"nctId":"NCT06107738","phase":"PHASE2","title":"Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma","status":"RECRUITING","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2023-12-21","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT05289492","phase":"PHASE1","title":"Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"iTeos Therapeutics","startDate":"2022-05-01","conditions":"Multiple Myeloma","enrollment":16},{"nctId":"NCT05899738","phase":"PHASE1","title":"A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-05-18","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT03310619","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-12-20","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular","enrollment":62},{"nctId":"NCT03161483","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-08-31","conditions":"Lupus Erythematosus, Systemic","enrollment":289},{"nctId":"NCT04933747","phase":"PHASE1","title":"Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-08-12","conditions":"Renal Insufficiency","enrollment":26},{"nctId":"NCT04882163","phase":"PHASE1, PHASE2","title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2021-10-10","conditions":"Lymphoma, B-Cell","enrollment":""},{"nctId":"NCT03824678","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-02-13","conditions":"Hepatic Impairment, Healthy Volunteers","enrollment":40},{"nctId":"NCT02185040","phase":"PHASE2","title":"A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-09-16","conditions":"Systemic Lupus Erythematosus","enrollment":42},{"nctId":"NCT02192489","phase":"PHASE2","title":"A Phase 2 Study With CC-220 in Skin Sarcoidosis","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2014-11-01","conditions":"Sarcoidosis","enrollment":""},{"nctId":"NCT01733875","phase":"PHASE1","title":"2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-11-01","conditions":"Healthy","enrollment":65},{"nctId":"NCT03294603","phase":"PHASE1","title":"Radiolabeled Study of CC-220 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-09-11","conditions":"Healthy Volunteer","enrollment":6},{"nctId":"NCT03135509","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-05-24","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT02820935","phase":"PHASE1","title":"Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2016-07","conditions":"Pharmacokinetics","enrollment":36},{"nctId":"NCT02034773","phase":"PHASE1","title":"3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule","status":"COMPLETED","sponsor":"Celgene Corporation","startDate":"2013-05","conditions":"Healthy Volunteers","enrollment":64}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"SEPSIS"},{"count":1,"reaction":"BREAST CANCER RECURRENT"},{"count":1,"reaction":"CORNEAL EPITHELIUM DEFECT"},{"count":1,"reaction":"FALSE POSITIVE INVESTIGATION RESULT"},{"count":1,"reaction":"HUMAN CHORIONIC GONADOTROPIN INCREASED"},{"count":1,"reaction":"MALIGNANT MELANOMA"},{"count":1,"reaction":"PLASMACYTOMA"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"SQUAMOUS CELL CARCINOMA OF SKIN"},{"count":1,"reaction":"THERAPEUTIC PRODUCT EFFECT DECREASED"}],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Iberdomide","BMS-986382"],"phase":"phase_2","status":"active","brandName":"CC-220","genericName":"CC-220","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CC-220 is a small molecule that modulates the activity of cereblon, an E3 ubiquitin ligase, leading to the degradation of specific proteins involved in inflammation and immune responses. Used for Systemic lupus erythematosus, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":12,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}